Clinical Trial Results:
ASSESSMENT OF MULTIDRUG RESISTANCE IN BREAST CANCER AND LOW GRADE GLIOMA PATIENTS WITH [11C]TARIQUIDAR PET. A PILOT STUDY
Summary
|
|
EudraCT number |
2011-004189-13 |
Trial protocol |
AT |
Global end of trial date |
31 Aug 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Sep 2019
|
First version publication date |
21 Sep 2019
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
1
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Medical University of Vienna
|
||
Sponsor organisation address |
Spitalgsse 23, Viena, Austria, 1090
|
||
Public contact |
Department of Clinical Pharmacology, Medizinische Universität wien, 0043 1404002981, klin-pharmakologie@meduniwien.ac.at
|
||
Scientific contact |
Department of Clinical Pharmacology, Medizinische Universität wien, 0043 1404002981, klin-pharmakologie@meduniwien.ac.at
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
30 Sep 2016
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
31 Aug 2016
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
31 Aug 2016
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
To correlate PET imaging outcome parameters (e.g. volume of distribution (VT) of [11C]tariquidar in tumor tissue) at staging with Pgp expression levels measured by IHC and/or at baseline (diagnostic biopsy)
|
||
Protection of trial subjects |
Subjects were during the trail under the supervision of a physician or an experienced Nurse.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
02 Jan 2012
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Austria: 7
|
||
Worldwide total number of subjects |
7
|
||
EEA total number of subjects |
7
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
7
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||
Recruitment
|
||||||||||
Recruitment details |
Subjects were recruited by use of data base of the Dep. of Clinical Pharmacology, Medical University of Vienna. | |||||||||
Pre-assignment
|
||||||||||
Screening details |
Check of the in- and exclusion criteria, physical examination, vital signs, laboratory assessment | |||||||||
Period 1
|
||||||||||
Period 1 title |
Overall trial (overall period)
|
|||||||||
Is this the baseline period? |
Yes | |||||||||
Allocation method |
Not applicable
|
|||||||||
Blinding used |
Not blinded | |||||||||
Arms
|
||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||
Arm title
|
Group B, Breast cancer | |||||||||
Arm description |
- | |||||||||
Arm type |
Experimental | |||||||||
Investigational medicinal product name |
[11C]tariquidar
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Solution for injection/infusion
|
|||||||||
Routes of administration |
Intravenous bolus use
|
|||||||||
Dosage and administration details |
60 min, total effective dose <3 mSv for an i.v. injected activity amount of 400 MBq.
|
|||||||||
Arm title
|
Group G, Glioma | |||||||||
Arm description |
- | |||||||||
Arm type |
Experimental | |||||||||
Investigational medicinal product name |
[11C]tariquidar
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Solution for injection/infusion
|
|||||||||
Routes of administration |
Intravenous bolus use
|
|||||||||
Dosage and administration details |
60 min, total effective dose <3 mSv for an i.v. injected activity amount of 400 MBq.
|
|||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Group B, Breast cancer
|
||
Reporting group description |
- | ||
Reporting group title |
Group G, Glioma
|
||
Reporting group description |
- |
|
|||||||||||||
End point title |
Correlation of [11C]tariquidar PET imaging outcome parameters at staging with [1] | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
60 min
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Due to unsuccessful recruitment not enough subjects were involved in the study in order to make a statistical analysis. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
03.10.2013-31.08.2016
|
||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
22.0
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||
Substantial protocol amendments (globally) |
|||||||
Were there any global substantial amendments to the protocol? Yes | |||||||
Date |
Amendment |
||||||
14 Oct 2015 |
Change in study protocol, cover letter and patient information letter |
||||||
15 Dec 2015 |
Change in patient information letter, study protocol |
||||||
Interruptions (globally) |
|||||||
Were there any global interruptions to the trial? Yes | |||||||
|
|||||||
Limitations and caveats |
|||||||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||||||
None reported |